BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15201672)

  • 1. De novo malignancies after intestinal and multivisceral transplantation.
    Abu-Elmagd KM; Zak M; Stamos JM; Bond GJ; Jain A; Youk AO; Ezzelarab M; Costa G; Wu T; Nalesnik MA; Mazariegos GV; Sindhi RK; Marcos A; Demetris AJ; Fung JJ; Reyes JD
    Transplantation; 2004 Jun; 77(11):1719-25. PubMed ID: 15201672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients: improved outcomes with new outlooks.
    Abu-Elmagd KM; Mazariegos G; Costa G; Soltys K; Bond G; Sindhi R; Green M; Jaffe R; Wu T; Koritsky D; Matarese L; Schuster B; Martin L; Dvorchik I; Nalesnik MA
    Transplantation; 2009 Oct; 88(7):926-34. PubMed ID: 19935465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppression, Race, and Donor-Related Risk Factors Affect De novo Cancer Incidence Across Solid Organ Transplant Recipients.
    Bhat M; Mara K; Dierkhising R; Watt KDS
    Mayo Clin Proc; 2018 Sep; 93(9):1236-1246. PubMed ID: 30064826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data.
    Jain AB; Yee LD; Nalesnik MA; Youk A; Marsh G; Reyes J; Zak M; Rakela J; Irish W; Fung JJ
    Transplantation; 1998 Nov; 66(9):1193-200. PubMed ID: 9825817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.
    Kauffman HM; Cherikh WS; Cheng Y; Hanto DW; Kahan BD
    Transplantation; 2005 Oct; 80(7):883-9. PubMed ID: 16249734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignancy after Solid Organ Transplantation: Comprehensive Imaging Review.
    Katabathina VS; Menias CO; Tammisetti VS; Lubner MG; Kielar A; Shaaban A; Mansour J; Surabhi VR; Hara AK
    Radiographics; 2016; 36(5):1390-407. PubMed ID: 27618321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three years clinical experience with intestinal transplantation.
    Abu-Elmagd K; Todo S; Tzakis A; Reyes J; Nour B; Furukawa H; Fung JJ; Demetris A; Starzl TE
    J Am Coll Surg; 1994 Oct; 179(4):385-400. PubMed ID: 7522850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation.
    Aguiar D; Martínez-Urbistondo D; D'Avola D; Iñarrairaegui M; Pardo F; Rotellar F; Sangro B; Quiroga J; Herrero JI
    Ann Transplant; 2017 Mar; 22():141-147. PubMed ID: 28302995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De novo malignancies after liver transplantation: a major cause of late death.
    Fung JJ; Jain A; Kwak EJ; Kusne S; Dvorchik I; Eghtesad B
    Liver Transpl; 2001 Nov; 7(11 Suppl 1):S109-18. PubMed ID: 11689783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Monitoring of Donor-specific Anti-HLA Antibodies After Intestine/Multivisceral Transplantation: Significance of De Novo Antibodies.
    Kubal C; Mangus R; Saxena R; Lobashevsky A; Higgins N; Fridell J; Tector AJ
    Transplantation; 2015 Aug; 99(8):e49-56. PubMed ID: 25769071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal and multivisceral transplantation immunosuppression protocols--literature review.
    Trevizol AP; David AI; Dias ER; Mantovani D; Pécora R; D'Albuquerque LA
    Transplant Proc; 2012 Oct; 44(8):2445-8. PubMed ID: 23026616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectrum of De Novo Cancers and Predictors in Liver Transplantation: Analysis of the Scientific Registry of Transplant Recipients Database.
    Zhou J; Hu Z; Zhang Q; Li Z; Xiang J; Yan S; Wu J; Zhang M; Zheng S
    PLoS One; 2016; 11(5):e0155179. PubMed ID: 27171501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High rates of de novo malignancy compromise post-heart transplantation survival.
    Giuliano K; Canner JK; Etchill E; Suarez-Pierre A; Choi CW; Higgins RSD; Hsu S; Sharma K; Kilic A
    J Card Surg; 2021 Apr; 36(4):1401-1410. PubMed ID: 33567114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal and multivisceral transplantation in children.
    Kato T; Tzakis AG; Selvaggi G; Gaynor JJ; David AI; Bussotti A; Moon JI; Ueno T; DeFaria W; Santiago S; Levi DM; Nishida S; Velasco ML; McLaughlin G; Hernandez E; Thompson JF; Cantwell P; Holliday N; Livingstone AS; Ruiz P
    Ann Surg; 2006 Jun; 243(6):756-64; discussion 764-6. PubMed ID: 16772779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
    Zanfi C; Lauro A; Cescon M; Dazzi A; Ercolani G; Grazi GL; Zanello M; Vivarelli M; Del Gaudio M; Ravaioli M; Cucchetti A; Vetrone G; Tuci F; Di Gioia P; Lazzarotto T; D'Errico A; Bagni A; Faenza S; Siniscalchi A; Pironi L; Pinna AD
    Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation.
    Saigal S; Norris S; Muiesan P; Rela M; Heaton N; O'Grady J
    Liver Transpl; 2002 May; 8(5):482-7. PubMed ID: 12004349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolutionary experience with immunosuppression in pediatric intestinal transplantation.
    Bond GJ; Mazariegos GV; Sindhi R; Abu-Elmagd KM; Reyes J
    J Pediatr Surg; 2005 Jan; 40(1):274-9; discussion 279-80. PubMed ID: 15868597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [De novo cancer after solid organ transplantation: Epidemiology, prognosis and management].
    Guillemin A; Rousseau B; Neuzillet C; Joly C; Boussion H; Grimbert P; Compagnon P; Duvoux C; Tournigand C
    Bull Cancer; 2017 Mar; 104(3):245-257. PubMed ID: 28237352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo malignancy in heart transplant recipients: A single center experience in Japan.
    Kimura Y; Yanase M; Mochizuki H; Iwasaki K; Toda K; Matsuda S; Takenaka H; Kumai Y; Kuroda K; Nakajima S; Watanabe T; Ikura MM; Wada K; Matsumoto Y; Seguchi O; Fukushima S; Fujita T; Kobayashi J; Fukushima N
    J Cardiol; 2019 Mar; 73(3):255-261. PubMed ID: 30587457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and survival patterns of solid organ transplant patients developing de novo colon and rectal cancer.
    Papaconstantinou HT; Sklow B; Hanaway MJ; Gross TG; Beebe TM; Trofe J; Alloway RR; Woodle ES; Buell JF
    Dis Colon Rectum; 2004 Nov; 47(11):1898-903. PubMed ID: 15622583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.